Upload
ava-petersen
View
36
Download
0
Embed Size (px)
DESCRIPTION
Journal Club. Alcohol, Other Drugs, and Health: Current Evidence January–February 2012. Featured Article. Association between Marijuana Exposure and Pulmonary Function Over 20 Years. Pletcher MJ, et al. JAMA. 2012;307(2):173–181. Study Objective. - PowerPoint PPT Presentation
Citation preview
1
Journal Club
Alcohol, Other Drugs, and Health: Current Evidence
January–February 2012
2
Featured Article
Association between Marijuana Exposure
and Pulmonary Function Over 20 Years
Pletcher MJ, et al. JAMA. 2012;307(2):173–181.
3
Study Objective
• To analyze the association between current and lifetime marijuana use and pulmonary function.
4
Study Design
• Longitudinal study* that assessed pulmonary function and smoking from 1985–2006 in a cohort of 5115 men and women from 4 US cities.
• Participants underwent baseline examination and 6 follow-up examinations.
• Pulmonary function testing was performed at baseline and years 2, 5, 10, and 20.
• Lifetime exposure to marijuana was expressed in joint-years, with 1 joint-year of exposure equivalent to smoking 365 joints or filled pipe bowls.
*Coronary Artery Risk Development in Young Adults (CARDIA) study.
5
Assessing Validity of an Article About Harm
• Are the results valid?
• What are the results?
• How can I apply the results to patient care?
6
Are the Results Valid?
• Did the investigators demonstrate similarity in all known determinants of outcomes? Did they adjust for differences in the analysis?
• Were exposed patients equally likely to be identified in the two groups?
• Were the outcomes measured in the same way in the groups being compared?
• Was follow-up sufficiently complete?
7
Did the investigators demonstrate similarity in all known determinants of
outcomes? Did they adjust for differences in the analysis?
• Mixed linear modeling was used to account for individual age-based trajectories of pulmonary function and other covariables*, including tobacco use, which was analyzed in parallel as a positive control.
• Approximately equal numbers of self-identified “black, not Hispanic” and “white, not Hispanic” men and women were recruited to ensure an adequate sample of the largest minority group in the US at baseline (1985).
*Race, sex, age, height, waist circumference, secondhand smoke exposure, exposure to airborne particulates (using study-city yearly averages), education level, and asthma.
8
Were exposed patients equally likely
to be identified in the groups?
Yes.
−The sample included only participants (n=5016) whose visits provided complete data on pulmonary function, smoking behavior (tobacco and marijuana), secondhand smoke exposure, height, and waist circumference.
9
Were the outcomes measured in the same way in the groups being
compared?
Yes.
− Forced expiratory volume in the first second of expiration (FEV1) and force vital capacity (FVC) were measured in the same way for all participants.
10
Was follow-up sufficiently complete?
• Participants contributed an average of 3.9 pulmonary-function measurements per person over the course of 20 years.
• Fifty-six percent of the sample (2807 participants) attended the year-20 examination.
11
What are the Results?
• How strong is the association between exposure and outcomes?
• How precise is the estimate of the risk?
How strong is the association between exposure and outcome?
How precise is the estimate of the risk?
• In adjusted models that considered 4-level categorizations of current and lifetime exposure, compared with zero exposure,
– FVC increased with greater lifetime exposure in joint-years
(p=0.01), and FEV1 increased with greater lifetime exposure of up to 10 joint-years and then declined to 36 mL (95% CI, −6.5 to 79) greater than the zero exposure level (p=0.049).
– FVC increased with smoking intensity up to 20 marijuana smoking episodes in the past 30 days and then declined to 20 mL greater than the zero exposure level (p=0.03).
13
How Can I Apply the Results to Patient Care?
• Were the study patients similar to the patients in my practice?
• Was the duration of follow-up adequate?
• What was the magnitude of the risk?
• Should I attempt to stop the exposure?
14
Were the study patients similar to the patients in my practice?
• The sample was comprised of black and white women and men from 4 large US cities who were aged 18–30 years and healthy at enrollment in 1985.
15
Was the duration of follow-up adequate?
• The follow-up period was 20 years.
16
What was the magnitude of the risk?
• Low level marijuana exposure was not associated with declines in pulmonary function.
• The study was not able to confirm whether heavy marijuana exposure was associated with impairments in pulmonary function.
17
Should I attempt to stop the exposure?
• From a pulmonary standpoint, there appears to be no adverse impact from low-level marijuana exposure.